A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

[1]  C. Gedye,et al.  The RANK–RANKL axis: an opportunity for drug repurposing in cancer? , 2019, Clinical and Translational Oncology.

[2]  P. V. van Dam,et al.  RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. , 2019, Critical reviews in oncology/hematology.

[3]  S. Peters,et al.  RANKL signaling sustains primary tumor growth in genetically engineered mouse models of lung adenocarcinoma , 2017, bioRxiv.

[4]  S. Peters,et al.  Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer , 2013, Current opinion in oncology.

[5]  G. Scagliotti,et al.  Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  E. Oldfield,et al.  Reduced cell proliferation by IKK2 depletion in a mouse lung cancer model , 2012, Nature Cell Biology.

[7]  Aleksey A. Porollo,et al.  p62 is a key regulator of nutrient sensing in the mTORC1 pathway. , 2011, Molecular cell.

[8]  D. Feldser,et al.  Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. , 2011, Cancer discovery.

[9]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[11]  M. Widschwendter,et al.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.

[12]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[13]  A. Baldwin,et al.  Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. , 2010, Cancer research.

[14]  D. Feldser,et al.  Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.

[15]  B. Fingleton,et al.  Epithelial NF-κB activation promotes urethane-induced lung carcinogenesis , 2007, Proceedings of the National Academy of Sciences.

[16]  M. Fukuoka,et al.  Skeletal metastases in non-small cell lung cancer: a retrospective study. , 2007, Lung cancer.

[17]  Sanja Dugonjić,et al.  [Incidence and imaging characteristics of skeletal metastases detected by bone scintigraphy in lung cancer patients]. , 2006, Vojnosanitetski pregled.

[18]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[19]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[20]  M. Krzakowski,et al.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[22]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[23]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.